AgomAb Therapeutics N.V. (‘AgomAb’), a privately held Belgian biotherapeutics company developing agonistic antibodies for the regeneration of damaged tissues, announces today that it has secured additional financing in an extension to its Series A financing round from new investor Andera Partners.
AgomAb Therapeutics N.V., a privately held Belgian biotherapeutics company developing agonistic antibodies for regeneration of damaged tissues, announces today that it has secured €21m in a Series A financing round from a strong international investor syndicate.
By continuing to use the site, you agree to the use of cookies. Privacy Policy
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Recent Comments